The Impact of FDA’s Evolving Regulatory Environment on MSL Compliance and KOL Engagement

In today’s dynamic regulatory landscape, Medical Affairs professionals and Medical Science Liaisons (MSLs) face unprecedented shifts that require strategic agility and heightened compliance. The U.S. FDA is implementing significant changes including the prohibition of pharmaceutical employees from serving on advisory committees, novel expedited pathways for rare disease drug approvals, and internal restructuring affecting regulatory negotiations. These developments are reshaping expectations for scientific exchange and KOL (Key Opinion Leader) engagement models, placing new demands on Medical Affairs teams to adapt swiftly.

Medical Affairs must now take a proactive stance in facilitating compliant scientific dialogue, supporting early evidence generation, and ensuring robust documentation standards. This comprehensive review of the new regulatory changes also provides actionable guidance for medical affairs to navigate these changes effectively while reinforcing the strategic value of medical affairs.

Regulatory Shifts: Fundamental Changes Impacting Medical Affairs Strategy

1. Exclusion of Industry Representatives from FDA Advisory Committees

In April 2025, the FDA fortified its stance to eliminate potential conflicts of interest by formally banning pharmaceutical employees from participating in advisory committees. While intended to preserve the integrity of regulatory advisory processes, this policy significantly impacts Medical Affairs:

• There is now an increased reliance on external KOLs. With industry voices restricted, there is an amplified emphasis on independent KOL input for regulatory discussions. Medical Affairs now has the opportunity to identify and engage with a broader network of KOLs who can provide expert opinions during regulatory reviews.
• Compliance risk is now amplified. MSL-KOL interactions require vigilant compliance oversight to ensure discussions remain non-promotional, factual, and aligned with FDA guidance on scientific exchange. Any misstep could lead to perceptions of undue influence or promotional activities.

Here are some key strategies to keep in mind as a result:

1. Develop criteria for KOL selection that prioritize scientific expertise, experience with regulatory processes, and absence of conflicts of interest.
2. Ensure all interactions with KOLs are well-documented, have clear objectives, and adhere to compliance policies to foster transparent relationships.
3. Utilize advisory boards effectively by setting clear agendas focused on scientific and clinical insights, avoiding any promotional discussions.

Medical Affairs leaders must operationalize KOL engagement frameworks that emphasize transparency, documentation, and appropriate firewalls from commercial functions. Regular compliance and ethical engagement training should be mandatory for all team members involved in KOL interactions.

2. Expedited Approvals for Rare Diseases*

The proposal for a new expedited pathway for rare disease therapies [1] accelerates timelines traditionally reserved for post-marketing commitments. Medical affairs can participate in:

• Pre-Approval Scientific Communications: There is a greater focus on educating HCPs about investigational agents under expanded access programs. MSLs play a crucial role in facilitating these discussions. Remember: MSLs should be well-versed in pre-approval information exchange (PIE) regulations to engage appropriately with HCPs regarding investigational products. Any communication must remain consistent with the investigational status of the therapy. MSLs must avoid extrapolating investigational efficacy or safety data beyond what is supported by clinical evidence. Clear communication about eligibility, risks, and benefits of expanded access programs is essential to maintain trust and compliance.
• Evidence Generation Support: Medical Affairs can contribute significantly to real-world evidence (RWE) strategies by collaborating on early-phase clinical studies, investigator-initiated studies, registries, and patient advocacy initiatives. This involvement can enhance understanding of unmet medical needs and inform product development.
• Patient Advocacy Engagement: Engaging with patient advocacy groups can provide valuable insights into patient needs and experiences, which can inform clinical trial designs and support evidence generation efforts.

*As of the posting date of this blog post, this expedited pathway has not yet been implemented.

3. FDA Restructuring: Gaps in Regulatory Feedback

A recent internal FDA restructuring resulted in significant downsizing of the negotiation teams [2], introducing uncertainty in regulatory dialogues. This organizational change may lead to delays or gaps in feedback during the approval process. As a result, medical affairs must be involved in building proactive evidence packaging. Medical Affairs must assist in anticipating regulatory data queries by developing comprehensive, clear, and concise evidence packages that preemptively address potential concerns. Increased interaction with Clinical Development, Regulatory Affairs, and Research & Development is essential to construct cohesive evidence narratives pre-submission. This alignment ensures that all teams present unified and consistent information to regulators.

Here are some key strategies to keep in mind as a result:

1. Medical Affairs professionals should deepen their expertise in regulatory science and evidence generation processes to help bridge potential communication voids. This includes staying updated on regulatory guidances, attending relevant workshops, and possibly obtaining accredited training in regulatory affairs.
2. Establish regular cross-functional meetings to share updates, align on strategies, and address any emerging issues promptly. Teams can also work together to develop contingency plans for various regulatory outcomes to ensure readiness for different scenarios.
3. Utilize data management and analytics tools to generate insights and prepare for regulatory submissions efficiently. These tools can also be used to actively monitor regulatory trends, review precedents, and analyze competitor activities to inform strategic planning.

Conclusion

Medical Affairs organizations must recalibrate field medical strategies to remain agile amidst the FDA’s evolving regulatory policies. Critical success factors include:

• Transparent KOL Engagement Practices: Prioritizing scientific value and compliance in all interactions to build trust and credibility.
• Rigorous Documentation: Implementing audit-ready documentation processes that demonstrate adherence to regulations and internal policies.
• Early Scientific Integration into Clinical Development: Collaborating closely with R&D and Regulatory Affairs to align on evidence generation and regulatory strategies.
• Comprehensive MSL Training on Regulatory Pathways: Equipping teams with the knowledge to navigate complex regulatory environments and communicate effectively with stakeholders.

To navigate this evolving landscape, Medical Affairs teams must remain agile, informed, and compliant. Particularly in how they engage with KOLs, support evidence generation, and align with regulatory strategy. Continued education in areas like regulatory science, health economics, and clinical development can help strengthen their impact. Professional development programs, such as, offer a structured way for teams to build this expertise and strengthen their regulatory readiness and strategic impact. Now is the time to invest in the skills that will define the next generation of Medical Affairs leadership.

FAQs

Q1: How can Medical Affairs teams support expedited rare disease product development?
Medical Affairs can play a pivotal role by:

• Collaborating on Clinical Trial Design:
• Supporting Expanded Access Programs (EAPs)
• Engaging with Patient Advocacy Groups
• Facilitating Real-World Data Collection
• Navigating Ethical Considerations

Q2: How is KOL engagement evolving with the FDA’s ban on pharma participation in advisory committees?
KOL engagement is becoming more critical, so field-based medical affairs teams must keep in mind the key strategies to KOL engagement to remain compliant, such as:

• Keeping interactions focused on genuine scientific dialogue, knowledge sharing, and collaborative problem-solving.
• Clearly disclose any financial or consulting relationships, and ensure that KOLs are aware of their obligations regarding conflicts of interest.
• Ensuring that all materials and discussions are balanced and evidence-based, without promotional intent.
• Implementing feedback mechanisms. MSLs should gather and act upon feedback from KOLs to improve engagement strategies and address any concerns.

By embracing these best practices and staying informed about regulatory changes, medical affairs professionals and MSLs can navigate the evolving landscape effectively. Continuous learning and adherence to ethical standards will support their vital role in advancing healthcare outcomes.

References

[1] Manalac, T. Biospace. Makary Discusses Expedited Rare Disease Approvals Pathway, ‘Public Distrust’ in New Interview. Apr 2025. https://www.biospace.com/policy/makary-discusses-expedited-rare-disease-approvals-pathway-public-distrust-in-new-interview#:~:text=The%20FDA%20is%20eyeing%20a,in%20an%20interview%20on%20Friday.

[2] Fick, M. Taylor, M. Reuters. FDA fires most negotiators for pharma user fee talks, sources say. Apr 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-fires-most-negotiators-pharma-user-fee-talks-sources-say-2025-04-17/